SAN DIEGO, Aug. 1 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced that it has been awarded a contract by the Space and Naval Warfare Systems Center San Diego (SSC San Diego) in an amount totaling approximately $1.6 million over the next two years. The contract award was made by SSC San Diego under the Defense Advanced Research Projects Agency (DARPA) sponsored BioFluidic Chips (BioFlips) and Simulation Tools for Chemical/Biological Microsystems Program. The objective of the DARPA contract is to develop and refine electronically driven sample preparation protocols on specifically designed microelectronic chips. The intended samples will simulate a panel of biowarfare related agents found in blood. Pursuant to the contract, extracted DNA from the microelectronic chips will be processed for detection using Nanogen's electronic hybridization technique. "We are very pleased to have been accepted as a recipient of this contract award," commented Howard Birndorf, Chairman, Chief Executive Officer and President of Nanogen. "The electronically-driven sample preparation chip will enable Nanogen to expand upon our electronic hybridization technology and move closer towards an automated sample-to-answer system for DNA diagnostics. We believe Nanogen's technology may lead to important advances in biological warfare defense, in addition to our core focus in the medical research, medical diagnostics and forensic areas." Nanogen recently began marketing its NanoChip(TM) system to scientists and genomics laboratories setting new standards for SNP scoring. The NanoChip(TM) system has been shown to provide accuracy equal to or better than DNA sequencing and other methods for SNP confirmation. Unlike other systems, the NanoChip(TM) system uses electronically accelerated hybridization under very low salt conditions, potentially avoiding problems with DNA conformation and secondary structures, whereas most sequencing and primer extension technologies require high salt conditions. The NanoChip(TM) system allows the user to array and analyze DNA on its NanoChip(TM) cartridges in user selected formats in a single day with walk-away automation. The NanoChip(TM) system integrates advanced microelectronics and molecular biology into a platform technology with broad commercial applications in the fields of biomedical research, genomics, medical diagnostics, genetic testing and drug discovery. The Company has established corporate alliances as part of its strategy to expand the applications and accelerate the commercialization of products derived from its technology. This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the contract's research and goals will be achieved, whether the Company's NanoChip(TM) system can be or will be further successfully commercialized, products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether the Company's collaborations will continue to be funded and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company's Form 10-K, as amended, for the year ended December 31, 1999 and subsequent reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. CONTACT: Kieran T. Gallahue, Senior Vice President and Chief Financial Officer, 858-410-4600, of Nanogen; or Media, Page Sargisson of Noonan/Russo Communications, 415-677-4455, ext. 229
SOURCE Nanogen, Inc.